CoreWeave Q1 2026 Revenue Surges as AI Infrastructure Demand Grows 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
Oil Prices Surge as U.S.-Iran Conflict Threatens Strait of Hormuz Supply Route 
Trump Invites Top CEOs Including Nvidia, Apple, Boeing to China Summit With Xi Jinping 
Asian Stocks Slide as Iran Tensions Escalate Despite Strong Weekly Gains 
UOB Q1 Profit Meets Expectations as Loan Growth Offsets Lower Interest Rates 
Gold Prices Hold Firm as Iran Tensions and Dollar Swings Drive Safe-Haven Demand 
U.S.-China Beef Trade Deal Hopes Rise Ahead of Trump-Xi Summit 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
Shell Q1 Profit Surges to Two-Year High as Dividend Rises Despite War-Driven Debt Pressure 
Sony Forecasts Lower 2027 Profit Despite Strong Music and Sensor Growth 
Russian LNG Shadow Fleet Expands Amid Arctic LNG 2 Sanctions 
China-Made Fireworks Power U.S. Independence Day Celebrations Amid Trade Truce 
Continental AG Shares Jump After Q1 Profit Beats Expectations 
China Banks Halt New Loans to Sanctioned Refineries Amid U.S.-Iran Oil Crackdown 
Nike Tariff Refund Lawsuit Sparks Consumer Backlash Over Price Increases 
Celltrion’s antibody treatment for COVID-19 has been granted approval for emergency use in Peru. The South Korean pharmaceutical company announced on Monday, Nov. 22, that the Peruvian authorities approved its Regkirona treatment for emergency application on adult patients with COVID-19.
According to Yonhap News Agency, Peru authorized Celltrion’s antibody treatment for emergency use based on recent results of phase three clinical study of the drug. The study was for attaining more comprehensive results for Regkirona’s effectiveness and safety, and since the results were good, it was approved.
The antibody treatment is being administered to patients in the form of an intravenous injection. It was said to be directly injected for 60 minutes.
Peru is the latest country to issue approval on Celltrion’s drug for treating COVID-19. It has already won approval from other states, such as Brazil and Indonesia, for emergency application. In its home base, which is South Korea, Regkirona has already won the authorities’ drug safety conditional approval in February.
One of the best things about the new drug is that it can lower the risk of COVID-19’s progress to severe levels. What’s more, Celltrion previously stated that its antibody treatment could also reduce the recovery time of patients.
Celltrion’s Regkirona is also South Korea’s very first COVID-19 treatment and it secured approval from Peru just a week after receiving marketing approval from the European Commission. The monoclonal antibody treatment was given the go-ahead last week.
Today’s achievement, coupled with Committee for Medicinal Products for Human Use (CHMP) positive opinion for Regdanvimab, underscores our ongoing commitment to addressing the world’s greatest health challenges,” Celltrion Healthcare’s head of medical and marketing, Dr. HoUng Kim, Ph.D., said in a press release. “Typically, the recommendations from the CHMP are passed on to the EC for rapid legally binding decisions within a month or two, however, given the unprecedented times, we have received the EC approval within a day.”
Meanwhile, the medical and marketing chief added that they are currently in talks with contractors and governments in 30 countries more across Asia, Europe, and Latin America. Celltrion said it would continue to work to make sure that COVID-19 patients worldwide will have access to safe and effective treatment.
